Skip to main content
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.

Publisher: Bentham Science Publishers

More about this publication?
Volume 3, Number 3, 2007

Articles

Paraoxonase-1 (PON1) as a Predictor of Biochemical Outcomes in Farmers
pp. 175-182(8)
Authors: Antonio F. Hernandez; Olga Lopez; Gloria Pena; Jose L. Serrano; Tesifon Parron; Lourdes Rodrigo; Fernando Gil; Antonio Pla

Favourites:
ADD

Vascular Endothelial Growth Factor (VEGF) in Pleural Effusions
pp. 183-188(6)
Authors: Theodoros S. Kiropoulos; Zoe Daniil; Konstantinos I. Gourgoulianis; Epaminondas Zakynthinos

Favourites:
ADD

Regulation of Oxidative Phosphorylation by Inhibition of its Enzyme Complexes via Reversible Phosphorylation
pp. 189-206(18)
Authors: Sebastian Vogt; Annika Rhiel; Verena Koch; Bernhard Kadenbach

Favourites:
ADD

Histone Deacetylase Inhibitors: Novel Immunomodulators
pp. 207-215(9)
Authors: Yaping Sun; Pavan Reddy

Favourites:
ADD
Favourites:
ADD

Ruthenium Complex as Enzyme Modulator: Modulation of Lactate Dehydrogenase by a Novel Ruthenium(II) Complex Containing 4-Carboxy N-Ethylbenzamide as a Ligand
pp. 243-253(11)
Authors: Surendra K. Trigun; Raj K. Koiri; Lallan Mishra; Santosh K. Dubey; Santosh Singh; Pankaj Pandey

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content